From the Department of Surgery, University of Sydney, and the Renal Units of the Royal Prince Alfred and Sydney hospitals (address reprint requests to Dr. May at the Royal Prince Alfred Hospital ...

Governor Dennis Pineda's plan to bring affordable dialysis services closer to the Kapampangans is now starting to become a reality.This, as the provincial gover ...

Autologous arteriovenous access is the key to long-term success with hemodialysis and is strongly supported by the National Kidney Foundation's Dialysis Outcomes Quality Initiative guidelines.

Systems announced that the six-month results from the randomized arm of the WRAPSODY Arteriovenous Access Efficacy trial ...

A research team led by Professor Park Hoon-seok of Nephrology at Catholic University of Korea's Seoul St. Mary's Hospital and clinical instructor Ryu Se-young at Incheon St. Mary's Hospital recently ...

Good morning, ladies and gentlemen. Welcome to the Humacyte Fourth Quarter Results Conference Call. Currently all participants are in listen-only mode. Later we'll conduct a question-and-answer ...

FDA Approval: The FDA granted full approval for Symvess on December 19, 2024 for use in adults as a vascular conduit for extremity arterial injury when urgent revascularization is needed to avoid ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: ...

The WRAPSODY CIE received premarket approval (PMA) from the US Food and Drug Administration (FDA) in December 2024. Merit began commercialization of the device in the United States in January 2025.

Transparent, well-designed clinical trials are a must. FastWave Medical's Scott Nelson has advice on how to get there.